167 related articles for article (PubMed ID: 25232492)
21. Epigenetic silencing of BCL6B inactivates p53 signaling and causes human hepatocellular carcinoma cell resist to 5-FU.
Li X; Yu J; Brock MV; Tao Q; Herman JG; Liang P; Guo M
Oncotarget; 2015 May; 6(13):11547-60. PubMed ID: 25909168
[TBL] [Abstract][Full Text] [Related]
22. Identification of hypermethylation in hepatocyte cell adhesion molecule gene promoter region in bladder carcinoma.
Tao J; Liu Q; Wu X; Xu X; Zhang Y; Wang Q; Luo C
Int J Med Sci; 2013; 10(13):1860-7. PubMed ID: 24324362
[TBL] [Abstract][Full Text] [Related]
23. Epigenetic silencing of TMEM176A activates ERK signaling in human hepatocellular carcinoma.
Li H; Zhang M; Linghu E; Zhou F; Herman JG; Hu L; Guo M
Clin Epigenetics; 2018 Nov; 10(1):137. PubMed ID: 30400968
[TBL] [Abstract][Full Text] [Related]
24. Methylation of Tip30 promoter is associated with poor prognosis in human hepatocellular carcinoma.
Lu B; Ma Y; Wu G; Tong X; Guo H; Liang A; Cong W; Liu C; Wang H; Wu M; Zhao J; Guo Y
Clin Cancer Res; 2008 Nov; 14(22):7405-12. PubMed ID: 19010857
[TBL] [Abstract][Full Text] [Related]
25. Tissue factor pathway inhibitor-2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma.
Wong CM; Ng YL; Lee JM; Wong CC; Cheung OF; Chan CY; Tung EK; Ching YP; Ng IO
Hepatology; 2007 May; 45(5):1129-38. PubMed ID: 17464989
[TBL] [Abstract][Full Text] [Related]
26. Silencing HOXD10 by promoter region hypermethylation activates ERK signaling in hepatocellular carcinoma.
Guo Y; Peng Y; Gao D; Zhang M; Yang W; Linghu E; Herman JG; Fuks F; Dong G; Guo M
Clin Epigenetics; 2017; 9():116. PubMed ID: 29075359
[TBL] [Abstract][Full Text] [Related]
27. The silencing of RECK gene is associated with promoter hypermethylation and poor survival in hepatocellular carcinoma.
Zhang C; Ling Y; Zhang C; Xu Y; Gao L; Li R; Zhu J; Fan L; Wei L
Int J Biol Sci; 2012; 8(4):451-8. PubMed ID: 22419890
[TBL] [Abstract][Full Text] [Related]
28. ZIC1 is downregulated through promoter hypermethylation in gastric cancer.
Wang LJ; Jin HC; Wang X; Lam EK; Zhang JB; Liu X; Chan FK; Si JM; Sung JJ
Biochem Biophys Res Commun; 2009 Feb; 379(4):959-63. PubMed ID: 19135984
[TBL] [Abstract][Full Text] [Related]
29.
Anwar SL; Krech T; Hasemeier B; Schipper E; Schweitzer N; Vogel A; Kreipe H; Buurman R; Skawran B; Lehmann U
World J Gastroenterol; 2017 Mar; 23(9):1568-1575. PubMed ID: 28321157
[TBL] [Abstract][Full Text] [Related]
30. Epigenetic silencing of Aristaless-like homeobox-4, a potential tumor suppressor gene associated with lung cancer.
Liu WB; Han F; Du XH; Jiang X; Li YH; Liu Y; Chen HQ; Ao L; Cui ZH; Cao J; Liu JY
Int J Cancer; 2014 Mar; 134(6):1311-22. PubMed ID: 24037716
[TBL] [Abstract][Full Text] [Related]
31. Methylome analysis and integrative profiling of human HCCs identify novel protumorigenic factors.
Neumann O; Kesselmeier M; Geffers R; Pellegrino R; Radlwimmer B; Hoffmann K; Ehemann V; Schemmer P; Schirmacher P; Lorenzo Bermejo J; Longerich T
Hepatology; 2012 Nov; 56(5):1817-27. PubMed ID: 22689435
[TBL] [Abstract][Full Text] [Related]
32. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.
Schagdarsurengin U; Gimm O; Hoang-Vu C; Dralle H; Pfeifer GP; Dammann R
Cancer Res; 2002 Jul; 62(13):3698-701. PubMed ID: 12097277
[TBL] [Abstract][Full Text] [Related]
33. Identification of genes and pathways, including the CXCL2 axis, altered by DNA methylation in hepatocellular carcinoma.
Subat S; Mogushi K; Yasen M; Kohda T; Ishikawa Y; Tanaka H
J Cancer Res Clin Oncol; 2019 Mar; 145(3):675-684. PubMed ID: 30564899
[TBL] [Abstract][Full Text] [Related]
34. Clinical significance of aberrant cyclin-dependent kinase-like 2 methylation in hepatocellular carcinoma.
Zhou Y; Qiu XP; Li ZH; Zhang S; Rong Y; Yang GH; Fang-Zheng
Gene; 2019 Jan; 683():35-40. PubMed ID: 30292871
[TBL] [Abstract][Full Text] [Related]
35. Frequent silencing of RASSF1A via promoter methylation in follicular thyroid hyperplasia: a potential early epigenetic susceptibility event in thyroid carcinogenesis.
Brown TC; Juhlin CC; Healy JM; Prasad ML; Korah R; Carling T
JAMA Surg; 2014 Nov; 149(11):1146-52. PubMed ID: 25229773
[TBL] [Abstract][Full Text] [Related]
36. Methylation-associated silencing of death-associated protein kinase gene in laryngeal squamous cell cancer.
Kong WJ; Zhang S; Guo C; Zhang S; Wang Y; Zhang D
Laryngoscope; 2005 Aug; 115(8):1395-401. PubMed ID: 16094112
[TBL] [Abstract][Full Text] [Related]
37. Delta-like 3 is silenced by methylation and induces apoptosis in human hepatocellular carcinoma.
Maemura K; Yoshikawa H; Yokoyama K; Ueno T; Kurose H; Uchiyama K; Otsuki Y
Int J Oncol; 2013 Mar; 42(3):817-22. PubMed ID: 23337976
[TBL] [Abstract][Full Text] [Related]
38. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
[TBL] [Abstract][Full Text] [Related]
39. Promoter methylation of the secreted frizzled-related protein 1 gene SFRP1 is frequent in hepatocellular carcinoma.
Shih YL; Shyu RY; Hsieh CB; Lai HC; Liu KY; Chu TY; Lin YW
Cancer; 2006 Aug; 107(3):579-90. PubMed ID: 16795071
[TBL] [Abstract][Full Text] [Related]
40. Epigenetic reactivation of RASSF1A by phenethyl isothiocyanate (PEITC) and promotion of apoptosis in LNCaP cells.
Boyanapalli SS; Li W; Fuentes F; Guo Y; Ramirez CN; Gonzalez XP; Pung D; Kong AN
Pharmacol Res; 2016 Dec; 114():175-184. PubMed ID: 27818231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
